Back to Dashboard









AbbVie Inc. (ABBV)
Real-time intraday values
Market Overview
From:
To:
ABBV Intraday
No data available
SymbolABBV
IPO DateJan 2, 2013
CEOMr. Robert A. Michael CPA
Full Time Employees57k
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUnited States
ExchangeNYSE
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +1.01% | +2.87 US$ |
| 5 Days | -2.92% | -8.61 US$ |
| 1 Month | +0.57% | +1.62 US$ |
| 6 Months | +32.78% | +70.72 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of ABBV...
Key Statistics
Market Cap
505.89B
P/E Ratio
49.18
Div Yield
2.44%
52W High
$302.93
52W Low
$190.75
Analyst Consensus
ConsensusBuy
Bullish2379.3%
Neutral517.2%
Bearish13.4%
52W Analyst Price Targets
Min Target
$237.00
$237.00
Max Target
$350.00
$350.00
Current$286.42
Avg Target$315.88
Analyst Recommendations
Target Price:$315.88($237.00 - $350.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on ABBV
Join the community to share your analysis
Latest News for ABBV

Is Solid Tumor Partnership Altering The Investment Case For AbbVie (ABBV)?
Simply Wall St.•Nov 21, 2026, 12:12 AM

5 High-Yield Healthcare Stocks for a Tax-Free Roth IRA Income Stream
24/7 Wall St.•Nov 20, 2026, 05:15 PM

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy for 2027?
Motley Fool•Nov 20, 2026, 04:20 PM

Should You Buy Jazz Pharmaceuticals Stock For Its Cash?
Trefis•Nov 20, 2026, 03:27 PM

Senate Passes Landmark Permitting Bill. Here’s Who Could Benefit.
Barrons.com•Nov 20, 2026, 03:20 PM


Should You Buy Bristol Myers Squibb Stock At Today's Discount?
Trefis•Nov 20, 2026, 02:51 PM

Jim Cramer Says Cardinal Health Is “the Stock That Is Made for This Moment”
24/7 Wall St.•Nov 20, 2026, 02:47 PM

AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
PR Newswire•Nov 20, 2026, 01:00 PM
iShares U.S. Healthcare ETF (IYH) Sells $17.4 Million of Eli Lilly on Wednesday
GuruFocus.com•Nov 20, 2026, 11:05 AM